Xoma (Details Narrative) - USD ($) $ in Thousands	Jun. 21, 2023	Mar. 31, 2024
Milestone payment, amount	$ 6,000
Payments for royalities	$ 6,000
XOMA [Member]
Assignment and assumption agreement description	Pursuant to the Assignment Agreement, the Company is entitled to receive (i) a one-time payment of $1 million upon acceptance of a re-submission of an NDA to the FDA for arimoclomol, and (ii) a one-time payment of $1 million upon the first invoiced sale in certain territories of a pharmaceutical product derived from arimoclomol as an active pharmaceutical ingredient, subject to the receipt of the applicable regulatory approval required to sell such a product in such countries. In January 2024, Zevra announced the FDA had accepted the NDA for arimoclomol and the Company received the one-time payment of $1 million in February 2024 recognized such net proceeds of $1.0 million as other income in the statement of operations for the period ended March 31, 2024
Royalty Purchase Agreement [Member]
Payments for royalities	$ 1,000
Aldrorubicin And Arimoclomol [Member]
Legal fees	5,000
Arimoclomol [Member]
Milestone payment, amount		$ 3,650
Commercial sale, amount	1,000
Aldoxorubicin [Member]
Commercial sale, amount	$ 4,000